Roivant Sciences Ltd. $ROIV Shares Newly Acquired by Englebert Financial Advisers LLC

Englebert Financial Advisers LLC acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 26,071 shares of the company’s stock, valued at approximately $953,000. Roivant Sciences comprises approximately 0.9% of Englebert Financial Advisers LLC’s investment portfolio, making the stock its 25th largest position.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Quadrant Capital Group LLC boosted its stake in Roivant Sciences by 1.8% during the third quarter. Quadrant Capital Group LLC now owns 50,124 shares of the company’s stock worth $1,672,000 after buying an additional 878 shares during the period. Nisa Investment Advisors LLC increased its position in Roivant Sciences by 79.5% during the third quarter. Nisa Investment Advisors LLC now owns 12,530 shares of the company’s stock valued at $458,000 after acquiring an additional 5,550 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd purchased a new stake in shares of Roivant Sciences in the third quarter valued at $2,257,000. Cordatus Wealth Management LLC purchased a new stake in shares of Roivant Sciences in the third quarter valued at $357,000. Finally, SteelPeak Wealth LLC purchased a new stake in shares of Roivant Sciences in the third quarter valued at $309,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Activity

In related news, insider Mayukh Sukhatme sold 144,756 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $36.48, for a total value of $5,280,698.88. Following the completion of the sale, the insider owned 18,630,739 shares in the company, valued at approximately $679,649,358.72. The trade was a 0.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $36.62, for a total value of $7,324,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,599,154 shares in the company, valued at approximately $58,561,019.48. This trade represents a 11.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,622,688 shares of company stock valued at $58,826,636. Corporate insiders own 8.80% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on ROIV. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Roivant Sciences in a report on Wednesday, August 19th. Wolfe Research downgraded shares of Roivant Sciences from an “outperform” rating to a “peer perform” rating in a report on Monday, October 12th. Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. Finally, Stifel Nicolaus began coverage on shares of Roivant Sciences in a research report on Wednesday, September 16th. They issued a “buy” rating and a $51.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Roivant Sciences has a consensus rating of “Moderate Buy” and an average target price of $45.64.

Roivant Sciences Price Performance

Shares of ROIV opened at $34.92 on Wednesday. The firm has a fifty day moving average price of $36.58 and a 200-day moving average price of $33.20. Roivant Sciences Ltd. has a 12-month low of $17.54 and a 12-month high of $42.50.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The company had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. On average, sell-side analysts anticipate that Roivant Sciences Ltd. will post -2.00 earnings per share for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.